Research study looks at best treatment options to relieve pain for diabetes-related neuropathy
Published on 26 September 2022
Picture: Professor Solomon Tesfaye (middle left) with members of the OPTION-DM trial team at Sheffield Teaching Hospitals NHS Foundation Trust
Professor Solomon Tesfaye, Research Director of Diabetes and Endocrinology, and Consultant Physician/Endocrinologist at Sheffield Teaching Hospitals NHS Foundation Trust, who led the study, said: “This trial brings focus on the plight of people who suffer from painful neuropathy and will lead to increased awareness and improved treatment for patients. Despite large variations in the cost and availability of each medication, it is reassuring that amitriptyline, duloxetine and pregabalin, and their combinations are similar in their effectiveness for relieving pain and so this study has great potential to influence treatment guidelines for DPNP, not only in the UK, but across the world. I would like to thank all the patients who participated in this long and demanding trial.”
The results from the OPTION-DM trial will be instrumental in improving treatment and quality of life for patients suffering with DPNP.
The report said: “To our knowledge, this was the largest and longest ever, head-to-head, crossover neuropathic pain trial. We showed that all three monotherapies and their combinations had similar analgesic efficacy. Combination treatment was well tolerated and led to improved pain relief in patients with suboptimal pain control with a monotherapy.”
Read the report in The Lancet
Read the DRWF information leaflet How can diabetes affect my feet?
Support DRWF by making a donation here
Find out more about DRWF-funded research here
Find out more about DRWF fundraising here
To receive the charity’s latest bulletins as they become available, please sign up here
Read DRWF diabetes information leaflets here
Join the Diabetes Wellness Network here
I would like to make a regular donation of
I would like to make a single donation of